News Angle produces new data backing liquid biopsy in cancer Angle hopes Parsortix will be first approved cell-based liquid biopsy.
Partner Content Partner Content STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics STORM Therapeutics Exclusive Speaker Interview
News GSK to take blood cancer drug into late-stage trials UK firm to get back into cancer with GSK2857916
News Gilead goes full throttle on CAR-Ts with $567m acquisition Gilead hopes CDL technology will create therapies targeting solid tumours
News Immunocore’s rare cancer treatment gains UK Promising Medici... Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
